NIFTY to hit 28,300! Part 3 of the Market Strategy 2025 by ICICI Direct research gives our top picks to ride this wave! A 🧵.
Piramal Pharma (PIRPHA)
A pharma powerhouse, excelling in CRDMO and complex hospital generics, and well-positioned for growth in GLP-1 and ADCs.
Target Price: ₹ 320 (26% Upside)
(1/n)
Piramal Pharma (PIRPHA)
A pharma powerhouse, excelling in CRDMO and complex hospital generics, and well-positioned for growth in GLP-1 and ADCs.
Target Price: ₹ 320 (26% Upside)
(1/n)
Loading suggestions...